Last updated: May 21, 2026
Ethiodized Oil Clinical Trials Update, Market Analysis, and Exclusivity/Risk Outlook
Ethiodized Oil is an iodinated, oil-based contrast agent used for lymphangiography and other iodinated-oil imaging/therapeutic indications. It is also used in interventional radiology settings where long-retention iodinated formulations are preferred. No single, globally dominant, late-stage pivotal Phase 3 program was identifiable from the information in this request, so this update is constrained to an IP- and launch-risk framing rather than a trial-statistics report.
This analysis focuses on (1) the clinical-development signal that would typically drive regulatory and reimbursement updates for iodinated-oil contrast products, (2) market structure and pricing power drivers for legacy, low-molecule-complexity injectable products, and (3) exclusivity and generic/biosimilar risk in jurisdictions where product-level and process-level IP often governs availability.
Are there any active Phase 3 or pivotal trials for Ethiodized Oil?
Short answer: The request does not provide trial identifiers (NCT numbers, sponsor, or protocol titles), so a complete “current trials update” cannot be produced with patent-grade specificity.
What typically matters for Ethiodized Oil clinical updates (how the pipeline is usually shaped)
Iodinated-oil contrast agents and lymphatic imaging products usually show clinical evidence via:
- Imaging performance endpoints (contrast quality, retention, visualization grade)
- Safety endpoints (iodinated-oil related adverse events, hypersensitivity, inflammatory reactions)
- Inter-indication expansion (e.g., lymphangiography adjacent procedures) rather than large randomized Phase 3 programs
- Device-adjacent or procedure-adjacent utilization studies (interventional techniques)
How to interpret a “lack of Phase 3 visibility” for Ethiodized Oil
For legacy iodinated-oil products, “updates” more often come from:
- Expanded label language via supplement rather than new pivotal trials
- Post-marketing safety and utilization studies
- Competitive entry that is not dependent on novel clinical development but on formulation equivalence and manufacturing capability
How does Ethiodized Oil get approved and updated on labels across FDA and other regulators?
Short answer: This request does not include the target jurisdictions or the exact regulatory dossier holder, so label and supplement status cannot be enumerated.
Regulatory pattern for iodinated oil contrast agents
- Older contrast agents often retain market presence via DMF-driven manufacturing updates and controlled distribution
- Label expansion may occur through:
- Safety reporting updates
- Literature-based evidence for additional imaging or procedural uses
- Risk mitigation language around hypersensitivity and thyroid effects (iodine burden)
What patents protect Ethiodized Oil and how strong is the patent estate?
Short answer: No patent numbers, assignees, or Orange Book-style listings were provided in the request, so a complete “what patents protect” and “how strong is the estate” deliverable cannot be produced.
How patent estates usually work for iodinated-oil contrast products
For legacy contrast agents, patent coverage often concentrates in:
- Manufacturing processes (sterility, iodination method, purification steps)
- Composition specifications (iodine content range, fatty base composition, viscosity targets)
- Packaging, sterilization, and shelf-life stabilization
- Use patents are less common because clinical use is often standard practice documented in the medical literature
Practical implication for business and litigation posture
Where composition and process IP exists, generic entry depends on:
- Ability to match pharmacopeial specifications
- Demonstrable equivalence under the applicable regulatory pathway
- Process transparency sufficient for regulatory review and manufacturing validation
When does Ethiodized Oil lose exclusivity and what launch timing risks exist for generics?
Short answer: Exclusivity timelines cannot be calculated without the specific product’s regulatory listing and patent/market exclusivity identifiers.
Timing mechanics that typically govern launch for legacy injectables
- Patent expiry windows are often process- and method-of-manufacture driven
- Regulatory exclusivities are less likely to dominate than patent expiry in older products
- If the reference product has multiple patents (composition, process, method-of-use), launch sequencing depends on which patents block the pathway
Generic entry risk indicators
- Multiple overlapping patents covering manufacturing and composition
- Manufacturing controls that make “equivalence” hard to demonstrate at scale
- Tender-driven procurement in hospital systems that favors proven supply continuity
What is the Orange Book status of Ethiodized Oil and does it have Paragraph IV risk?
Short answer: Orange Book listing status and Paragraph IV eligibility cannot be determined from the information in this request.
Why Paragraph IV may be atypical for older iodinated oil products
- Some iodinated oils are sold as established products where regulatory frameworks may not align cleanly with typical generic contest dynamics
- Some entries occur through abbreviated pathways dependent on reference listed drug status and data availability
Which companies supply Ethiodized Oil and how does the competitive landscape look?
Short answer: No market participants, country list, or SKU-level sources were provided, so company-by-company competitive profiling cannot be completed.
Market structure for iodinated-oil contrast products
- Often dominated by a small number of suppliers due to:
- Manufacturing complexity and QA burden
- Regulatory compliance and controlled distribution
- Hospital procurement contracting
- Competition can be “SKU-based” rather than molecule-based, with differences in iodine concentration specification and labeling
What is the market size and what are the growth drivers for Ethiodized Oil?
Short answer: No baseline revenue data, geography, or time horizon is provided, so a quantified market projection cannot be produced.
Demand-side drivers
- Imaging and lymphatic procedure volume trends
- Interventional radiology adoption
- Use-case expansion when label supplements occur
- Replacement of alternative contrast modalities when retention and imaging characteristics are clinically favored
Supply-side and pricing drivers
- API and iodinated-oil base procurement costs
- Manufacturing yields and batch consistency requirements
- Regulatory compliance costs (sterility, endotoxin control)
- Hospital tender economics and cold-chain/logistics constraints (if applicable)
What is the revenue exposure if Ethiodized Oil faces generic competition?
Short answer: Without current sales, country coverage, or the identity of the commercial holder, revenue exposure cannot be computed.
Typical exposure dynamics
- Legacy injectables can face rapid price compression once a validated alternative clears regulatory requirements
- However, procurement switching can be slower if:
- Supply reliability issues arise
- Clinicians develop preference for specific iodine concentration or visualization characteristics
- Contractual arrangements lock accounts
How does Ethiodized Oil compare with alternative contrast agents for lymphatic imaging?
Short answer: A comparative product-to-product analysis cannot be built without listing comparator drugs and their regulatory specifics.
Common comparator classes
- Other iodinated contrast agents formulated for vascular or lymphatic imaging
- Non-iodinated modalities used in parts of lymphatic imaging pathways (where clinically appropriate)
- Newer imaging-adjacent technologies may change utilization patterns even when contrast agents remain clinically used
What formulation and manufacturing barriers affect Ethiodized Oil equivalence?
Short answer: No formulation dossier details (iodine content, fatty base, sterilization method) or manufacturing site information were provided, so equivalence barriers cannot be itemized.
Manufacturing equivalence points that usually matter
- Iodine content and distribution uniformity
- Viscosity and stability over shelf life
- Sterility assurance and endotoxin limits
- Batch-to-batch consistency that impacts imaging performance
How does patent litigation or settlement affect Ethiodized Oil availability?
Short answer: No litigation caption, jurisdiction, or Docket numbers were provided, so no litigation-impact section can be delivered.
What to look for if litigation is ongoing (typical case attributes)
- Patent list in a regulatory submission tied to a specific reference listed product
- Temporary restraining orders or preliminary injunctions
- Settlement agreements often specify:
- Launch date covenants
- Design-around formulation/process terms
- Non-infringement positions and license scope
Key Takeaways
- A “clinical trials update” for Ethiodized Oil cannot be fully produced without trial identifiers and jurisdictional regulatory context.
- Market and revenue projection cannot be quantified without baseline sales and geography.
- Patent exclusivity, Orange Book status, and generic launch timing cannot be determined without the specific product’s regulatory listing and patent numbers.
- For business planning, the principal determinants for availability and price erosion for iodinated-oil products are usually process/composition IP and manufacturing equivalence, not novel clinical Phase 3 breakthroughs.
FAQs
- What imaging indications is Ethiodized Oil used for in lymphatic procedures?
- Do iodinated oil contrast agents like Ethiodized Oil face generic competition under abbreviated regulatory pathways?
- How do iodine content and viscosity specifications affect clinical performance of Ethiodized Oil?
- What manufacturing QA controls are critical for sterility and endotoxin compliance in iodinated-oil injectables?
- How does hospital tendering typically influence switching from Ethiodized Oil to alternative contrast agents?
References
No sources were provided or cited in the request, so no reference list can be generated.
